Pharmafile Logo
Pharmafocus logo
Advanced Search

Takeda

Showing 15 posts of 249 posts found.

Ninlaro

Takeda’s Ninlaro extends myeloma survival in trial

December 7, 2015
Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma

Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …

News

Takeda reveals five-year Adcetris survival data

December 6, 2015
Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology

Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …

News
kyprolis_amgen

Amgen’s Kyprolis doubles Velcade benefit in head-to-head study

December 5, 2015
Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma

Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …

News
Clinigen logo

Clinigen launches UK managed access program for Takeda’s ixazomib

November 30, 2015
Sales and Marketing Clinigen, Takeda, ixazomib, managed access, multiple myeloma, oncology

Clinigen and Takeda have struck a deal to allow patients in the UK to access the multiple myeloma drug ixazomib …

News
Takeda oncology

Challenges in oncology R&D – part 2

November 25, 2015
Manufacturing and Production, Research and Development R&D, Takeda, oncology

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …

Feature
Takeda oncology

FDA approves Takeda’s Ninlaro for multiple myeloma

November 23, 2015
Manufacturing and Production, Research and Development Takeda, myeloma

The US Food and Drug Administration (FDA) has approved Takeda’s Ninlaro (ixazomib) for use in combination with lenalidomide and dexamethasone …

News
Turing logo

Top five pharma controversies of 2015 (so far)

November 20, 2015
Medical Communications, Sales and Marketing AstraZeneca, Martin Shkreli, Philidore, Takeda, Turing Pharmaceutical, Valeant, Warner Chilcott, controversies, fraud, reputation, tax avoidance, turing

5. AstraZeneca forced to deny tax avoidance allegations

Feature
Takeda oncology

Challenges in oncology R&D

November 18, 2015
Manufacturing and Production, Research and Development Dixie-Lee Esseltine, Takeda, Takeda oncology, Velcade, multiple myeloma, oncology

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …

Feature
boris_johnson_in_japan

Mayor of London announces Takeda, UCL R&D partnership

October 14, 2015
Research and Development London, R&D, Takeda, UCL, neurology

Takeda is teaming up with researchers at University College London (UCL) to identify and validate novel target genes for the …

News
Takeda oncology

Takeda in Velcade patent blow

August 25, 2015
Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib

Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …

News

Takeda gets European MAA approval for ixazomib

August 21, 2015
Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma

Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …

News
contrave

Orexigen and Takeda reboot Contrave collaboration

August 12, 2015
Research and Development Contrave, FDA, Takeda, orexigen, weight loss drugs

Orexigen has agreed to foot the $200 million bill for a new trial to prove its claims that Contrave, the …

News
Takeda oncology

Takeda cancer drug gets EMA boost

July 29, 2015
Research and Development, Sales and Marketing Takeda, ixazomib, multiple myeloma

The EMA has granted Takeda an accelerated assessment for its multiple myeloma drug, ixazomib. The Agency’s Committee for Medicinal Products …

News
Entyvio

NICE u-turns on Entyvio for Crohn’s disease

July 10, 2015
Medical Communications, Sales and Marketing Crohn's, Crohn’s disease, Entyvio, Millenium, NICE, Takeda, funding

NICE has performed a u-turn and recommended drug treatment Entyvio for Crohn’s disease for routine NHS funding.In final draft guidance …

News

Adam Zaeske appointed as managing director of Takeda UK and Ireland

July 6, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adam Zaeske, Takeda

Japanese pharma firm Takeda has appointed Adam Zaeske as managing director of Takeda UK and Ireland.Zaeske has been with Takeda …

Appointment
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025